ARCHIVES

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

FDA Committee Approves NDA for Mitxantrone

March 21, 1986

NCI, FDA Courting Drug Sponsors To Add Clinical Trials To PDQ Database

October 11, 1996

I-131 doses highest Near Nevada Test Site, Fallout Study Finds

November 17, 1989

New Treatment For CML Could Be Model for Molecular Target-Based Therapeutics

December 10, 1999

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

New Predictive Score May Help In Planning Adjuvant Therapy

September 26, 2008